The Latest Cardiac and Vascular News
WASHINGTON, Jan. 13, 2026 /PRNewswire/ — A novel approach to removing excess fluid through the skin and a new strategy to prevent right ventricular failure after LVAD implantation are among the highlights of the January issue of the Journal of Cardiac Failure (JCF). Together, these…
The second issue of the open-access journal showcases multidisciplinary heart failure research and the many intersections that shape patient care. WASHINGTON, Nov. 19, 2025 /PRNewswire/ — The second issue of the Journal of Cardiac Failure-Intersections, online now, delivers a diverse…
KIRKLAND, Wash., Sept. 25, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced its debut at the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting, September 26–29 in Minneapolis, Minnesota. At booth #920, Kestra will feature its Cardiac Recovery System® (CRS) platform, anchored by the ASSURE® Wearable Cardioverter Defibrillator. The CRS platform closes the critical gap in sudden cardiac death protection by pairing protection with actionable insights that support confident care during the high-risk early phase of heart failure recovery. Attendees can explore the CRS platform through an immersive booth experience and hands-on demonstrations that highlight how it empowers clinicians, strengthens patient–provider connections, and supports recovery for vulnerable patients. “Our presence at HFSA underscores Kestra’s commitment to advancing care for heart failure patients,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “The Cardiac Recovery System platform redefines how sudden cardiac arrest risk is managed, equipping clinicians with technologies and insights that protect patients and strengthen recovery support.” Kestra will also participate in the Devices in Heart Failure Meeting on Friday, September 26, where attendees can see the ASSURE system up close and learn how it integrates into clinical workflows to support guideline-directed medical therapy. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. CONTACT: Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com
Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
Saturday Plenary to Spotlight Innovations in Heart Failure Research, AI, and Future Care Models WASHINGTON, July 24, 2025 /PRNewswire/ — The Heart Failure Society of America (HFSA) is marking 30 years of leadership in heart failure care with a dynamic celebration at the HFSA Annual…
WASHINGTON, July 18, 2024 /PRNewswire/ — The Heart Failure Society of America (HFSA) recently announced the selection of new officers and board members for the society with terms starting at the conclusion of the HFSA Annual Scientific Meeting 2024 (ASM), which will take place September…
ROCKVILLE, Md., June 7, 2023 /PRNewswire/ — The Heart Failure Society of America (HFSA) today announced the first cohort of heart failure (HF) providers to earn the Heart Failure Certification (HF-Cert). The multi-disciplinary certification recognizes HF providers who have demonstrated advanced-level knowledge and skill to provide competent heart failure services in the United […]
ROCKVILLE, Md., Feb. 6, 2023 /PRNewswire/ — A new joint guideline published today by the Heart Failure Society of America (HFSA) and the International Society for Heart and Lung Transplantation (ISHLT) addresses the growing availability and use of acute or temporary mechanical support devices. The joint guideline provides critical recommendations and protocols for the […]
Oak Ridge, TN, Jan. 19, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of America (HFSA) as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure. “The HFSA is the premier […]
Clinical Leadership and Management Call Scheduled for Wednesday, October 5, 2022, at 8:55am Eastern Time SUNNYVALE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its FDA designated Breakthrough CardiAMP® Cell Therapy […]
Statistically Significant Reduction in CV Mortality and HF Rehospitalizations as Compared to IV Diuretics at 30 and 90 Days MINNEAPOLIS, Oct. 03, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the results of the AVOID-HF […]
